Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy

NCT00858806 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
78
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Università degli Studi di Brescia